low-to-moderate - Healthcare spending is relatively recession-resistant (essential services), but elective procedures and outpatient volumes can decline 10-15% during recessions, reducing claim volumes. Employment levels affect insured population and claim activity. However, revenue cycle complexity increases during downturns as providers focus more intensely on cash collection and denial management, potentially driving module adoption.

Rising rates create moderate valuation headwind as high-multiple software stocks face higher discount rates (stock trades at 4.4x sales, down from likely 8-10x at IPO). Minimal direct business impact given negligible debt (0.01 D/E) and strong cash generation. However, healthcare provider customers may face higher financing costs for capital projects, potentially constraining IT budgets for discretionary software purchases.

growth - Investors attracted to recurring revenue SaaS model with 16% revenue growth, high gross margins, and expanding operating leverage. Recent 44% decline from highs reflects de-rating of high-multiple software stocks in rising rate environment and concerns about growth sustainability. Current 4.4x sales multiple at significant discount to SaaS peers (typically 6-12x), attracting value-oriented growth investors betting on re-rating as profitability scales.